Dr Dejan Juric speaks to ecancer at SABCS 2018 about the SOLAR-1 trial looking at alpelisib plus fulvestrant for advanced breast cancer.
He explains that line of therapy was looked into as a subgroup with the largest magnitude of effect seen in the second line setting.
Dr Juric also reports an analysis into PIK3CA mutation status in circulating tumour DNA, with PIK3CA mutant patients seeing an increased benefit.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
